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Abstract: Hydrogen isotopes are unique tools for identifying and 
understanding biological or chemical processes. Hydrogen 
isotope labeling allows for a traceless and direct incorporation of 
an additional mass or radioactive tag into an organic molecule 
with almost no change in its chemical structure, physical 
properties or biological activity. Using deuterium labeled 
isotopologues to study the unique mass spectrometric (MS)-
pattern generated from mixtures of biological relevant molecules 
drastically simplifies analysis. Such methods are now providing 
unprecedented levels of insight in a wide and continuously 
growing range of applications in the life sciences and beyond. 
Tritium (3H), in particular, has seen an increased utilization, 
especially in pharmaceutical drug discovery. The efforts and 
costs required for the synthesis of labeled compounds are more 
than compensated for by the enhanced molecular sensitivity for 
analysis and high reliability of the data obtained. In this review, 
advances in the applications of hydrogen isotopes in the life 
sciences are described.  
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For many years, hydrogen isotopes (deuterium and tritium) 
have been known for their utility in mechanistic, spectrometric, 
and tracer studies. Moreover, well known applications of 
hydrogen isotopes exist within almost every sub-discipline in life 
science, in nuclear science, and beyond.[1] Today, the ability for 
precise measurement of isotope ratios promotes a dynamic view 
on biosynthetic pathways, protein turnover, and systems-wide 
metabolic networks and, thus, has paved the way for a number 
of scientific breakthroughs in biomedical research.[2] In medicinal 
chemistry, replacement of hydrogen by deuterium has recently 
received much attention as a way to alter absorption, distribution, 
metabolism, and excretion (ADME) properties of drug 
candidates.[3]  
Thus, the objective of this review is to provide a brief 
perspective on the rapidly increasing applications of hydrogen 
isotopes in life science (Scheme 1). 
 
Scheme 1: Applications of hydrogen isotopes in different areas of the Life 
Sciences 
 
Hydrogen isotopes have many properties of ideal tracer 
nuclides. Both deuterium and tritium can be detected with very 
high sensitivity, applying conventional mass spectrometry for the 
former or radioactivity measurements for the latter. In recent 
years, the rapid development of high performance mass 
spectrometry has increased deuterium labeling applications 
significantly, while tritium continues to play a flagship role in drug 
discovery.[ 4 ] The popularity of hydrogen isotopes in the life 
sciences stems from their ability to allow for direct incorporation 
of a unique detection signal into the target molecule without 
changing its chemical structure, physical properties or biological 
activity. Consequently, hydrogen isotopes enable the detection 
and quantification of drug-related material or the discovery of 
new biological pathways in systems as complex as experimental 
animals or humans.[5]  
Deuterium is a stable isotope and thus can be handled under 
standard wet lab conditions without special permission, handling 
licenses, or radiation safety measures. This is not the case for 
tritium. Having said this, emissions are weak enough to make 
only minimum shielding necessary. Due to the long half-life (12.3 
years) of tritium, it is unnecessary to correct for decay during 
analysis. Thus, once prepared 3H-tracer can be stored and used 
for a long period of time if radiolytical decomposition can be 
minimised.  
Compared to 13C or 14C, hydrogen isotope labeling is 
typically easier, quicker, and much cheaper.[6] On the other hand, 
it is more difficult to predict the metabolic stability of 2H or 3H 
labeled compounds. In case of tritium, a reduced biologically 
tracer stability may result in an in vivo formation of highly toxic 
3H2O which can be distributed throughout the whole body and 
thus makes radioactivity measurement and quantification more 
difficult.[7]  
Incorporation of deuterium or tritium into an organic molecule 
can be achieved by two principle routes, either by a conventional 
multistep synthesis or by direct hydrogen isotope exchange 
(HIE). Depending on the complexity of the chemistry, the 
chemical structure of the target molecule, and the labeling 
position, a classical synthesis approach, starting from 
appropriate commercially available labeled precursors, can be 
very time and resource consuming. Therefore, methods for fast 
and convenient late stage introduction of deuterium or tritium 
into organic molecules were extensively investigated in recent 
years. The hydrogen isotope exchange (HIE)[ 8, 9] reaction allows 
for a selective installation of C±D[10] and C±T[11] bonds in the 
target molecule. Typically heterogeneous metal-catalyzed HIE 
generally results in relatively unspecific incorporation of 
numerous deuterium atoms into a molecular substrate. 
Accordingly, heterogeneous metal-catalyzed H/D exchange is 
typically the method of choice for preparation of stable 
isotopically labeled internal standards (SILS) for LC-MS/MS 
investigations. For SILS applications, the similarities of the mass 
signals for the unlabeled analyte relative to the signals for the 
internal standard should be as low as reasonably feasible. As a 
consequence, heterogeneous exchange methods have been 
optimized to incorporate 3 ± 5 deuterium atoms in the case of 
small molecules without chlorine, bromine, or sulfur-containing 
functionalities and where the remaining amount of unlabeled 
(D0) is negligible.[12] 
In contrast, homogeneous metal catalyzed HIE methods are 
typically much more selective incorporating deuterium only at 
specific positions in the molecule, e.g. next to a directing group. 
Therefore, these methods are of particular importance for tritium 
incorporation via H/T exchange[11]  The breadth of applications 
and molecular structures that require isotopic labeling ultimately 
demand a suite of synthetic methods in order to install the 
isotope in the desired position(s). These methods are 
highlighted in the connected review ³&-H Functionalization for 
+\GURJHQ,VRWRSH([FKDQJH´.[13] 
  
2. Applications of Deuterium labeled 
compounds 
Applications of deuterium can be distinguished based on 
four general concepts: 1. kinetic and equilibrium isotope effects; 
2. the generation of specific MS-patterns (e.g. 1:1 mixtures of 
labeled and unlabeled analyte); 3. the utilization for relative 
quantification based on changes of the ratio of labeled versus 
unlabeled analyte; and 4. the use for absolute quantification 
through internal standardization. The latter three applications are 
quite similar, as the underlying principle is the generation of a 
MS detectable mass shift compared to the unlabeled analyte. 
Consequently, those applications are not restricted to deuterium 
alone since a similar mass shift could also be achieved by 
employing other stable isotopes (e.g. 13C, 15N, or 18O). The 
question whether to use deuterium or another stable isotope 
label often depends on commercial availability, costs, and the 
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synthetic efforts needed for label introduction. Thus, in many 
cases, deuterium is preferred due to much cheaper precursor 
costs and the availability of highly efficient H/D exchange 
labeling approaches. However, for some specific applications 
(e.g. metabolomics pathway analysis) additional considerations 
may result in a preference for 13C. Whatever the choice of 
isotope, deuterium applications are typically reported in close 
conjunction with other stable isotopes, which makes it almost 
impossible to review deuterium applications alone.  
Consequently, this section has been expanded to cover 
stable isotope applications in general; however, whenever 
possible, with a particular focus on deuterium.  
 
2.1. The Kinetic Isotope Effect[14] 
Comparing C±H and C±D bonds, the activation energy for 
the C±D bond is larger. This difference is due to the greater 
mass of D versus H resulting in a lower vibrational frequency 
and, thus, a lower zero-point energy (ZPE) of the C±D bond 
(Scheme 2).[ 15 ] The lower energy relative to a C±H bond 
translates to a higher activation energy required to reach the 
transition state for bond cleavage and, thus, slower reaction rate 
of deuterated analogues when the rate-determining step 
involves breaking a covalent C±H/D bond. [ 16 ] This effect is 
known as the primary (kinetic) hydrogen isotope effect and is 
expressed as the ratio of the reaction rate constants for C±H 
versus C±D bond cleavage, with expected values of kH/kD > 1 
(normal KIE) or kH/kD < 1 (inverse KIE).[17] Substituting hydrogen 
for deuterium, large KIEs are observed because the relative 
mass change is great (100%), and even greater for tritium; 
however, KIEs can also occur for other isotopes, such as 11B, 
13C, 15N, 18O, and non heteroatomic bonds (e.g. D±D versus H±
H).[14] 
 
Scheme 2. Origins of the deuterium KIE: the lower zero-point energy (ZPE) 
results in a higher activation energy for C±D bond homolysis. 
Besides the semi-classical model, quantum mechanical 
tunnelling and related kinetic models are also invoked to explain 
KIEs.[18] The secondary hydrogen isotope effect arises in cases 
where the C±H or C±D bond remains intact during the rate-
limiting step of the reaction. Secondary KIEs are typically 
produced due to changes in hybridization (e.g. sp3 to sp2), or the 
involvement of hyperconjugation. Additionally, rates can be also 
influenced by a slightly reduced steric demand of the C±D bond 
(steric KIE), and the moderately increased ability of the C±D 
bond to donate electron density by an inductive effect (inductive 
KIE).[19 ] The magnitude of secondary isotope effects is much 
smaller than that of the primary KIEs, and typically in the range 
RI §-1.2 (noUPDO RU § -0.9 (inverse). The shifts in 
equilibrium upon isotopic substitution are termed equilibrium 
isotope effects (EIEs). Reactions may be also affected by the 
type of solvent used (for example, changing from H2O to D2O) if 
the solvent changes the isotopic composition by H/D exchange 
or the solvation of the activated complex.[20] Today, KIEs can be 
measured at natural abundance for nearly every type of reaction 
[21] or, in specific cases, even at the single-molecule level.[22] 
2.1.1. Isotope effects for investigation of chemical reaction 
mechanism 
Kinetic Isotope Effects (KIEs) have been extensively used to 
study reaction mechanisms by determining rate-limiting and 
product-determining steps (Scheme 3). KIEs are commonly 
measured using NMR[ 23 ] to detect isotope location and/or 
GC/MS and LC/MS[ 24 ] to detect mass changes. As KIEs are 
typically very sensitive to substrate and transition state structure, 
these measurements can be used to understand electronic, 
steric, and related effects.[ 25 ] KIE experiments are often 
designed and employed to support a computational hypothesis. 
Thus, the change of the reaction rate following replacement of 
an atom (typically hydrogen) by its isotope (deuterium) can be 
compared with the theoretical KIE values to provide essential 
experimental information on the calculated mechanistic 
pathway.[26]  
 
Scheme 3. Complementary deuterium KIE experiments: A) KIE determined 
from two parallel reactions; B) KIE determined from an intermolecular 
competition; and C) KIE determined from intramolecular competition.[27]  
Three different experimental designs are typically used (see 
Scheme 3). KIE determined from absolute rates of two parallel 
reactions; KIE determined from an intermolecular competition 
between deuterium-labeled and unlabeled substrate in the same 
reaction flask; and KIE determined from an intramolecular 
competition, e.g. mediated by placing a directing group (DG) 
between the C±H and C±D bonds. Apart from the differences in 
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feasibility and precision between the different kinds of 
experiments, they may also differ in terms of the information 
they provide.[ 27 ] Recent reviews of KIE applications for 
mechanistic studies include asymmetric,[ 28 ] organometallic,[ 29 ] 
and C±H bond activation[27] reactions. In addition to mechanistic 
investigations, KIE experiments have proved to be indispensable 
tools for understanding tunnelling[ 30 ] and dynamical 
phenomena.[31] 
In chemical synthesis, KIEs have been utilized only 
occasionally, e.g. to supress side product formation in 
cyclization reactions,[32] to facilitate C±H functionalization,[33] or 
to block ortho-lithiation.[34]   For example, the route for the total 
synthesis of í-N-methylwelwitindolinone C isonitrile  reported 
by Garg et al. features the strategic use of a deuterium kinetic 
isotope effect to improve the efficiency of a late-stage nitrene 
insertion reaction (scheme 4).[33] 
 
Scheme 4. Strategic use of KIE in total synthesis to facilitate C±H 
functionalization.[33]  
Apart from their use in relation to the kinetic isotope effect, 
stable isotopes are also utilized as tracers for mechanistic 
investigations to determine the nature of intermediates in 
chemical reactions[35] or to support the elucidation of biosynthetic 
pathways.[36] The focus in such studies is primarily the location 
and distribution of the label and, thus, following atoms through 
the synthetic assembly, e.g. by label-facilitated MS or NMR 
analysis.[29, 37]  
2.1.2. Isotope effects for determination of enzyme 
mechanism 
KIEs also provide a powerful tool to support the study of 
enzymatic mechanisms[38] and have been extensively utilized to 
deduce many aspects of enzyme chemistry (e.g. the mechanism 
of hydrogen transfer,[39] oxygen activation,[40] and acyl transfer 
reactions).[41] Similar to the experiments outlined in section 2.1.1 
for enzymatic mechanisms, KIEs are measured by direct 
comparison, equilibrium perturbation, or internal competition.  
The precision of the internal competition method has made it 
the most commonly used for investigating small KIEs.[42] KIEs 
can provide useful information for all parts of kinetic enzymatic 
mechanism studies.[ 43 ] In addition to the bond 
cleavage/formation step, enzymatic transformations involve 
multiple elementary steps, including substrate binding, 
conformational changes, and product release. Elementary steps 
that are not rate-limiting may still mask the isotope effect relating 
to the pertinent bond modification step; this then may result in an 
observed KIE that appears smaller than the intrinsic KIE for the 
key bonding event.[44] Accordingly, determining intrinsic isotope 
effects may require multiple labeling to measure several isotope 
effects for the same step.[45]  
 
2.1.3. Isotopes applied to improve existing drugs 
(deuterated drugs) 
Drugs administered to the body typically undergo biphasic 
metabolic transformation to facilitate elimination by increased 
water solubility.[46] The major metabolizing enzymes in human 
are from the cytochrome P450 enzyme family, accounting for 
75% of total drug metabolism and, thus, gaining much attention 
by the pharmaceutical industry.[ 47 ] Significant KIEs were 
observed for several P450-catalyzed reactions (Scheme 5),[48] 
particularly for dealkylations of ethers and amides, while amine 
N-dealkylation and aromatic hydroxylation reactions typically 
have low KIEs for mechanistic reasons.[49] Besides P450, other 
human metabolic enzymes, such as the aldehyde oxidase 
(AO)[50] and monoamine oxidase (MAO) family,[51] also produce 
measurable KIEs. This effect is utilized for quantification of 
native MAO enzyme activities, e.g. in relation to smoking, by a 
dual tracer approach comparing binding rates of selective PET 
radiotracers in the presence or absence of an additional 
deuterium label.[52]   
 
Scheme 5. Specific deuteration incorporation has the potential to impact the 
rate of metabolic transformations provided that the rate limiting step involves 
cleavage of a C±H bond. 
Depending on the enzymes involved and, hence, the 
mechanism of the rate-determining step, another consequence 
can be a different metabolic turnover of drug molecules when 
replacing hydrogen for deuterium.[53] Although, in principle, this 
has been known for many years,[ 54 ] the alteration of ADME 
properties by selective deuterium incorporation has only recently 
received much attention,[55] largely due to the business model of 
a number of new companies patenting and developing 
deuterated versions of existing therapeutic molecules.[ 56 ] 
Associated with this, the question whether a deuterated 
analogue of a known compound is obvious in light of prior art 
has been a subject for continuous debate,[ 57 ] with a recent 
tendency toward increased rejection of new patent applications 
for deuterated drug analogues.[58]  
The underlying principle in deuterated drugs being assessed 
as new drugs versus their unlabeled precursors relies on the 
assumption that specific deuterium labeling may result in 
potential beneficiary properties. Such properties include reduced 
systemic clearance and higher systemic exposure, as well as 
reduced formation of toxic or reactive metabolites, while 
retaining the potency of the original drug (Scheme 6).[3] 
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Consequently, potential drug benefits could include a reduced 
dosage or dosing regimen, a smaller potential for drug-drug 
interactions, and a lower incidence of side effects, resulting 
overall in an improved pharmacokinetic and safety profile, and 
enhanced effectiveness. However, it has become increasingly 
clear that prediction of the deuterium effect from in vitro data is 
difficult and, particularly for Cytochrome P450 (CYP)-mediated 
metabolism,[59] suppression of one pathway may not result in 
appreciable alteration of in vivo ADME properties as metabolic 
switching may promote alternative clearance routes.[60]  
 
 
Scheme 6. Potential pharmacological effects of specific drug deuteration: A: 
Metabolic shunting resulting in reduced exposure to undesirable metabolites 
(e.g. toxic or reactive); B: Reduced systemic clearance resulting in increased 
half-life; and C: Decreased pre-systemic metabolism resulting in higher 
bioavailability of unmetabolized drug.[3a]  
Significant clinical progress has been made in recent years 
regarding the use of deuterated drugs.[61] In 2017, the U.S. Food 
and Drug Administration (FDA) has accepted the New Drug 
Application (NDA) for SD-809 (now Austedo®),[ 62 ] for the 
treatment of chorea associated with Huntington disease, based 
on successful Phase 3 clinical trials.[63] SD-809 shows similar 
efficacy to tetrabenazine at lower doses and with a longer 
duration of action; thus, the dosing regimen was reduced from 
three times to only twice daily.[58]  
 
Scheme 7. Selected deuterated clinical drug development candidates and 
corresponding unlabeled original drugs. 
Other deuterated drugs, such as CTP-499 (deuterated 
pentoxifylline)[ 64 ] or AVP-786[ 65 , 66 ] (deuterated 
dextromethorphan), are currently in advanced clinical testing[67] 
or have demonstrated improved in vivo PK properties (Scheme 
7).[68]  
Instead of using deuterium to control metabolism and 
pharmacokinetic (PK) properties, another approach is 
Deuterium-Enabled Chiral Switching (DECS), which is employed 
in order to stabilize and characterize the preferred enantiomers 
for the racemic active ingredients of marketed drugs, which 
would otherwise interconvert.[69] 
 
2.1.4. Isotope effects in Toxicology 
Kinetic isotope effects can also be used as a tool to 
investigate metabolism-mediated target organ toxicities.[70] For 
example, 1,2Ǧdibromoethane caused greater DNA damage than 
its deuterium labeled analogue, suggesting that deuterium 
substitution led to a decrease in metabolism and, thus, a longer 
half-life of the DNA alkylating species.[71] In a second example, 
deuterochloroform (CDCl3) was reported to be up to 70% less 
toxic in rodents than CHCl3 because the decreased metabolic 
rate results in decreased formation of nephrotoxic phosgene.[72] 
Additionally, negative side effects associated with the 
consumption of alcohol can be diminished because of a 
significantly reduced rate of absorption and, thus, reduced peak 
concentration and delayed ingestion observed for deuterated 
ethanol.[73 ] Further examples include the application of stable 
isotope labeled N-methylformamide (NMF) in toxicogenomic 
studies for identification of potential genomic biomarkers of 
hepatotoxicity caused by related reactive metabolites (Scheme 
8).[74]  
 
Scheme 8. Metabolism of NMF leads to the formation of N-
(hydroxymethyl)formamide (pathway A) and methylisocyanate (pathway B). 
The deuterium on the formyl position is lost during the P450-catalyzed 
oxidation to methylisocyanate. The placement of deuterium(s) at either the 
formyl or the methyl positions can lead to metabolic switching. For example, 
deuteriums on the methyl group can lead to greater levels of methylisocyanate 
formation through pathway B as demonstrated in mice dosed with d3-
NMF.[70,74] 
2.1.5. Isotope effects in non-covalent interactions 
In addition to KIE involved in covalent bond forming or 
cleaving processes, isotope effects on non-covalent interactions 
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are also known, and mainly attributed to changes in polarity, 
polarizability, and molecular volume due to the shorter C±D 
bond length.[75] Deuteration of hydrocarbons typically results in 
more polar, less lipophilic molecules, while in presence of 
heteroatoms (e.g. N, O, S) the effect strongly depends on the 
position of deuterium. Although, in the vast majority of cases, 
unlabeled and deuterium labeled counterparts co-elute in 
reversed phase chromatography, the slight alteration of 
lipophilicity may affect retention times and can sometimesresult 
in resolution of the isotopologues (see Scheme 9).[76] This effect, 
known as chromatographic isotopic fractionation, has become 
even more relevant during recent years, due to the highly 
efficient chromatographic separations obtained by ultra-high 
performance liquid chromatography (UHPLC) instruments[ 77 ] 
and, accordingly, needs to be kept in mind particularly when 
using deuterated internal standards,[ 78 ] (see section 2.2.1) or 
within proteomic studies[ 79 ] (see section 2.3). Again, under 
standard LC-MS conditions in drug discovery (1-3 minutes 
overall elution time) the risk of misinterpreting quantitative 
analysis remains very small. 
 
Scheme 9. Chromatographic isotopic fractionation: in rare cases slight 
alterations in lipophilicity have the potential to change retention times and can 
result in resolution in C18 reversed phase chromatography: Example 
deuterated and non-deuterated HP185.[80] 
Generally, the number of deuterium substitutions increases 
the potential for chromatographic resolution; having stated this, 
label location, molecule size, molecule structure, retention 
mechanism, retention times, and mobile phase pH may also 
have an influence.[81] Furthermore, binding affinities can also be 
subject to deuterium isotope effects on van der Waals 
interactions and, thus, lead to stabilization or destabilization of 
binding to a ligand depending on the deuterium position.[75, 82]  
Selective deuteration can also influence the morphology and 
phase separation kinetics of polymer blends,[83 ] and alter the 
thermal, elastic,[84] and optoelectronic properties[85] of conducting 
polymers.[86]   
The deuteration of organic light-emitting diode (OLED) 
molecules,[87 ] such as tris-(8-hydroxyquinoline)aluminium[ 88 ] or 
tris-(2-phenylpyridine)iridium,[ 89 ] resulted in enhanced high-
voltage stability and quantum efficiency compared to the 
respective protonated OLED devices. Additionally, a strongly 
enhanced near-IR luminescence and increased lifetime was 
observed for ytterbium and neodynium cryptates upon 
deuteration.[90] As such, there is particular interest in deuterated 
molecules for use in OLED devices.[91] Deuterium substitution 
has been shown to change the superconducting transition 
temperature (Tc) in organic superconductors due to a reduced 
lattice volume and internal pressure originating from the smaller 
zero-point spacing of the C±D bonds.[92] It should also be noted 
that isotopic substitution can increase the scattering length 
density (SLD) contrast in neutron scattering measurements.[86] 
Thus, in combination with selective deuterium labeling, neutron 
scattering experiments can be used to study deformation 
mechanisms of polymers[93] and to investigate size, shape, and 
dynamic interactions of complex biological structures.[94] 
Introducing deuterium isotope chirality[95] in a monomeric unit 
can result in a cooperative structural chiral isotope effect,[ 96 ] 
leading to a preference for only one helical conformation of a 
dynamical racemic polymer and, thus, delivering supramolecular 
chirality (Scheme 10).[97] This amplification of isotopic chirality,[98] 
together with an asymmetric autocatalysis, have been discussed 
as potential pathways to biological homochirality.[99] 
 
Scheme 10. Structures and changes in optical activities in the conversion of 
deuterated monomeric isocyanates to the corresponding polyisocyanates. 
Circular dichroism studies of the two deuterated polymers demonstrate that 
the source of the chiral optical characteristics arise from the chromophore of 
the helix and, therefore, arise from a large excess of one helical sense in each 
polymer.[96a]  
 
Although general isotopic substitution is not expected to 
change solid state characteristics, for selected compounds 
isotopic polymorphism and, consequently, a change of crystal 
structure upon deuterium labeling have been reported.[ 100 ] 
Additionally, the molecular aggregation in the solid state can be 
sensitive to the use of deuterated solvents during the 
crystallization process.[101] 
In supramolecular systems, isotope effects on binding 
affinities, with enhanced stabilities observed for deuterated 
guests in self-assembled capsules,[ 102 ] could be due to the 
reduced steric interactions arising from the VKRUWHU&í'ERQGV
DVRSSRVHGWRVWURQJHUDWWUDFWLYH&'íʌLQWHUDFWions.[103] 
 
2.1.6. Stable isotope fractionation 
The natural abundance of stable isotopes, such as D (2H), 
13C, 15N and 18O, was fixed when the Earth was formed and, on 
the global scale, has not changed since.[104] However, due to the 
KIE, subtle variations in the isotopic composition, also known as 
isotopic fractionation,[105] can result in accumulation of heavier 
isotopes in the residual substrate fraction of biological, chemical, 
or physical degradation processes. As a result, the relative 
abundance measured in different materials can provide 
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important environmental information on their origin and 
history.[ 106 ] Accordingly, analysis of naturally abundant stable 
isotope ratios, e.g. by IRMS (Isotope Ratio MS),[ 107 ] IRIR 
(Isotope Ratio IR),[108] or ICP-MS (Inductively Coupled Plasma 
MS)[ 109 ] has been recognized as a powerful tool in forensic 
science, geochemistry, paleoclimatology, ecology, and 
physiology.[ 110 ] Applications are numerous and include, for 
example, the origin and/or counterfeit tracing of food,[ 111 ] 
water,[112] pollutants,[113] or pharmaceuticals,[114] and the isotopic 
characterization of drugs[115] and explosives,[116] as well as the 
fate assessment of contaminants in soils and aquifers.[117] Due to 
isotopic fractionation processes, D/H ratios of lipids vary 
substantially with growth conditions and, thus, the resulting 
patterns hold enormous potential as biogeochemical tracers.[118] 
Isotope ratio measurement also helps in the reconstruction of 
entire food webs and energy flows, from basal resources at the 
bottom to large consumers at the top.[ 119 ] Additionally, the 
method is applied in wildlife forensics to track the origin of 
migratory species[ 120 ] and in crime scene investigations for 
human provenancing.[121] Furthermore, stable isotope analysis of 
polar ice cores[ 122 ] or tree-rings[ 123 ] can provide retrospective 
insights into climatic and eco-physiological processes. Also, 
hydrogen isotope ratios in lunar rocks,[124] interplanetary dust 
particles,[ 125 ] meteorites,[ 126 ] and comets[ 127 ] can provide 
important information relating to our solar system and the 
universe. Moreover, stable isotope fractionation is known to 
occur as part of natural evaporation/condensation cycles 
(Scheme 11).[129] 
 
Scheme 11. Stable isotope fractionation occurs naturally through 
evaporation/condensation. Lighter isotopes preferentially evaporate while 
heavier isotopes condense preferentially to form precipitation. Thus, water 
molecules can be traced from their source to a given catchment based on 
fractionation ratios.[128]   
2.2. Stable isotopes in pharmaceutical drug discovery and 
development 
 
2.2.1. Isotope labeled internal MS Standards 
In recent years, liquid chromatography coupled with tandem 
mass spectrometry detection (LC-MS/MS) has become the most 
powerful bioanalytical tool for the investigation of samples 
originating from environmental, animal, and human studies.[129] 
For a quantitative LC-MS/MS analysis of an analyte in complex 
matrices (e.g. blood, urine, or bile), internal standards are 
considered essential. This helps compensate for matrix 
effects,[130] such as ion suppression,[131] and to account for any 
other potential variations during sample preparation and 
chromatography. Stable isotopically labeled internal standards 
(SILS) are particularly advantageous due to the similarity of the 
physical and chemical properties of the analyte and its standard. 
Both can be extracted from biological samples to the same 
extent and have identical retention times in chromatographic 
methods and ionization characteristics in the LC/MS but differ on 
account of their molecular masses. If this mass difference is 
large enough to avoid cross signal overlapping as a result of the 
natural isotope pattern, quantitative determination is possible 
(Scheme 12). The compound of interest is measured relative to 
the added internal standard by correlating a response ratio with 
a concentration ratio.[132]  
 
Scheme 12. Stable Isotope labeled internal standards need to have a 
sufficient mass difference (typically, for small molecules without chlorine, 
bromine or sulfur-containing functionalities, an incorporation of 3 to 5 
deuterium atoms) to avoid cross signal overlapping and negligible remaining 
M0.[133] 
Today, LC-MS/MS based assays are routinely developed for 
small molecule drug candidates very early in the pharmaceutical 
development timeline. This helps generate toxico- and 
pharmacokinetic information on the parent drug[134] and related 
metabolites[135] from animal and human studies. Stable isotope 
labeled CYP-specific probes are utilized for in vitro drug- drug 
interaction studies to facilitate e.g. LC-MS/MS-based high 
throughput screening of time dependent CYP inhibition for drug 
candidate profiling.[ 136 ] Similarly, stable labeled internal MS 
standards are also needed to analyse legal or illegal drugs, [137] 
for anti-doping testing,[138] for human bio-monitoring,[139] and for a 
wide range of environmental contamination testing, such as 
ecotoxicology and exposure analysis of air[ 140 ] and 
groundwater.[141]  
Following the strong increase in development of 
biopharmaceuticals, LC-MS/MS has recently attracted much 
interest as a viable alternative to the traditional ligand binding 
assays (LBA) for quantification of proteins.[ 142 ] Protein 
bioanalysis by LC-MS/MS offers several advantages over 
immunoassays, including higher throughput, and enhanced 
robustness, precision, and accuracy.[ 143 ] Due to the 
incompatibility with molecules larger than approx. 10 KDa, 
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protein quantification by LC-MS/MS usually includes proteolytic 
digestion to cleave the protein into a mixture of smaller 
peptides.[144] One such unit, the so called signature peptide, is 
then used for quantification along with an appropriate stable 
labeled internal standard as surrogate for the intact protein.[145] 
Compared to small molecule analysis, there are more options for 
internal standardization using either SILS or structural 
analogues of the intact protein or the signature peptide (Scheme 
13).[ 146 ] Recently, a stable isotopically labeled universal 
surrogate peptide for quantification of a wide variety of 




Scheme 13. Bioanalytical work flow and internal standardization for LC-MS 
quantification of proteins. 
Essentially the same strategy, known as AQUA (absolute 
quantification), is also applied in quantitative proteomics to 
determine absolute protein concentrations of, for example, 
unmodified and post-translational modified species.[148]  
During the synthesis of deuterated internal standards the 
possibile risk for a H/D back exchange needs to be considered 
for each reaction step and the conditions optimized accordingly. 
If HIE methods are applied on the final molecule itself, the 
exchange needs to be highly efficient to avoid a mass-
spectrometric cross-signal overlap with the remaining M0. This 
potential risk is sometimes mitigated by the use of 13C-
containing precursors, however connected with a higher costs 
and longer delivery times.  
2.2.2 Stable isotopes in metabolism studies 
Administration of radiolabeled drugs is essential in order to 
track the fate of a drug molecule throughout the body and 
excreta, and to distinguish drug-related material from 
endogenous components in complex biological mixtures.[149] The 
evolution of LC/MS technologies has shifted conventional 
radiolabeled metabolism studies with 14C-labelled drug 
candidates to later stages in drug development. And, besides 
tritium, stable isotope techniques are increasingly utilized in 
such biomedical research.[ 150 ] Compared to radioactivity 
detection, LC/MS analysis typically requires more intensive 
method development and validation in order to reach similar 
limits of quantification (LOQ). Additionally, only radioactivity 
detection with tritium ensures that unknown active metabolites 
are not overlooked and therefore tritium is still prefered for in 
vitro metabolism studies in pharmaceutical drug discovery, (see 
chapter 3.1).  
In cases where special radiation safety laboratories are not 
available, deuterium can provide useful information. Such 
applications often employ 1:1 mixtures of an unlabeled analyte 
with the corresponding stable isotope labeled analogue in order 
to generate specific MS patterns, with the resulting isotopic 
doublets providing higher sensitivity and selectivity. For 
example, 1:1 mixtures of unlabeled and stable isotope labeled 
compounds can be used for drug metabolite identification and 
quantification,[151] and to delineate underlying mechanisms and 
the enzymes involved.[152] Strategic placement of a 13C-label in a 
molecule can help to acquire the critical 13C-NMR data required 
to elucidate or confirm the structures of metabolites.[ 153 ] In 
source or online H/D exchange, utilizing deuterium-labeled 
solvents (such as D2O), is a technique that may be helpful to 
distinguish, for example, hydroxylations on carbon from 
oxidations on heteroatoms by generating a mass shift 
corresponding to the number of exchangeable protons on 
functional groups such as OH, NH2, or SH.[154] H/D exchange 
MS is also emerging as an efficient technique for probing protein 
conformational dynamics and protein interactions due to ligand 
binding, protein modification, and protein±protein interactions by 
monitoring the selective exchange of hydrogen for deuterium 
along a peptide backbone.[155]  
Metabolic bio-activation of drugs can also form metabolites 
that have intrinsic chemical reactivity and, therefore, have the 
potential to alter biological function and result in serious 
idiosyncratic adverse reactions.[156] Since direct detection and 
characterization of reactive metabolites[157] is extremely difficult, 
several 1:1 mixtures of labeled and unlabeled glutathione 
(GSH)[158] and glutathione derivatives[159](Scheme 14) have been 
introduced as trapping reagents to capture reactive metabolites 
by formation of stable GSH adducts.[160] 
 
Scheme 14. Labeled Glutathione and Gluthathione derivatives for 
characterization of reactive metabolites. 
2.3. Stable isotopes in mass-spectrometry based 
quantitative proteomics 
Mass spectrometry-based proteomics has become an 
indispensible tool in molecular, cellular and chemical biology, 
encompassing a variety of aspects, including protein primary 
sequence identification, analysis of post-translational 
modifications (PTMs), investigation of protein±protein 
interactions, and protein quantification.[161] Changes in relative 
abundance of proteins can be measured by quantitative MS 
analysis of the ratios of stable isotope labeled protein standards 
and the corresponding unlabeled protein samples.[ 162 ] Stable 
isotope introduction can be achieved by chemical modification or 
metabolic labeling of a protein. While the latter is limited to living 
cells, chemical labeling such as the isotope-coded affinity 
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reagent tags (ICAT) method[ 163 ] can be applied on any 
proteome, including body fluids and biopsy materials.  
 
Scheme 15. Structure of ICAT (Isotope-coded affinity tags) reagent 
comprising a cysteine-reactive group, a linker containing an isotope signature 
(heavy or light), and a biotin tag for avidin affinity separation.[164]  
 
Scheme 16. ICAT workflow for quantifying differential protein expression: two 
protein samples representing different cell states are labeled with the light or 
heavy ICAT reagent. The labeled protein mixtures are combined and 
proteolyzed. Tagged peptides are selectively isolated by avidin affinity 
chromatography and analyzed by MS. The relative abundance is determined 
by the ratio of signal intensities of the tagged peptide pairs.[164]  
The ICAT reagent consists of three elements: an affinity tag 
(biotin), a linker containing the stable isotope signatures, and a 
suitable group to react with cysteine (Scheme 15).[164] In the first 
step, proteins separately extracted from two different cell states 
(e.g. sick and healthy) are modified either by unlabeled or by 
deuterium labeled ICAT. After labeling, the proteins are pooled 
and digested with trypsin. The resulting modified peptides are 
isolated by avidin-based affinity chromatography and 
subsequently analyzed by LC/MS. Relative quantification is 
determined by the ratio of signal intensities of labeled and 
unlabeled peptide pairs (Scheme 16). Several variants have 
been developed in recent years for improvement and extension 
of the original method.[ 165 ] For example, cICAT (cleavable 
ICAT)[166] was introduced to allow acidic biotin removal prior to 
LC/MS analysis which enables database searches of free 
peptides. ICPL (isotope-coded protein labeling)[167] and stable 
isotope dimethyl labeling[168] were developed for labeling of free 
amino functions e.g. as in lysine (Scheme 17). 
 
Scheme 17. Labeling schemes of triplex stable isotope dimethyl labeling.[168]  
Isobaric tags[169] are mass normalized by introduction of an 
additional mass normalizing region and, thus, produce only a 
single peak for both healthy and sick samples. However, upon 
fragmentation, reporter ions with different masses are released 
due to individual weight differences between signature and mass 
balancer (Scheme 18) enabling MS characterization of both 
samples. Two isobaric tag families, TMT (Tandem Mass 
Tags)[170] and iTRAQ (Isobaric Tags for Relative and Absolute 
Quantification)[ 171 ] are commercially available for multiplex 
proteomics (Scheme 19), while IPTL (isobaric peptide termini 
labeling)[172] is currently under development. 
 
Scheme 18.  Isobaric tagging reagents workflow. [175]  
The stable isotope labeling with amino acids in cell culture 
(SILAC) concept involves growing two populations of cells but 
with only one group containing labeled essential amino acids in 
the medium.[173] Incorporation of the labeled amino acids into the 
proteome leads to a defined mass shift compared to the 
unlabeled population. After mixing and extraction, each peptide 
appears as a pair of labeled and unlabeled units in the MS and, 
thus, any intensity changes upon different cell treatments also 
indicate changes in abundance (Scheme 20).[ 174 ] SILAC is 
widely used in proteomics for protein expression profiling of 
normal vs. diseased cells and for identification and quantification 
of proteins.[175] Recently, SILAC was also used in vivo to label 
xenograft tumors derived from human colon cells.[176] 




Scheme 19. A) Structure of TMT (Tandem Mass Tags) and iTRAQ (Isobaric 
Tags for Relative and Absolute Quantification) reagents; and B) TMTsixplex 
structure and isotopic masses of reporter ions for the 13C, 15N versions. The 
mass normalized TMT tag results in six different reporter ions ranging from 
126 Da to 131 Da upon fragmentation. [166]  
 
Scheme 20. SILAC workflow: A) Standard SILAC: Cells are cultivated in the 
presence of either normal or stable isotope labeled amino acids (e.g. Leu-d3), 
resulting in differentially labeled proteins (heavy or light). After digestion, each 
peptide appears as a doublet with distinct mass. The ratio of intensities for 
such peptide pairs accurately reflects the abundance ratio for the 
corresponding proteins. In the MS spectra, SILAC can be used to quantify 
differences in steady-state protein levels, e.g. normal vs. deseased. B) pulsed 
SILAC: Cells cultivated in normal light (L) medium are transfected differently 
and subsequently pulse-labeled by transferring them to culture medium 
containing medium-heavy (M) or heavy (H) isotope-labeled amino acids, 
respectively. pSILAC can be employed to measure differences in protein 
synthesis upon different treatment. C) dynamic SILAC can reveal protein 
turnover by measurement of stable isotope incorporation/losses.[165]  
Stable isotope labeling in mammals (SILAM) was developed 
to introduce a stable isotope label, typically 15N, 
comprehensively into an entire rodent by providing food that 
contains only labeled proteins.[177] Consequently, differences in 
protein expression between a labeled and an unlabeled rodent 
can be analyzed by mass spectrometry. SILAM is used to study 
in vivo pathways or processes that are up- or down-regulated as 
a function of disease.[178]  
Recently, organism-wide isotopic labeling was also used to 
monitor protein turnover rates on thousands of individual 
proteins in different organs by measuring protein 
synthesis/degradation ratios through stable isotope tracer 
incorporation/losses.[179] The methodology, in this context, also 
named dynamic SILAC (Scheme 20), is fully translatable from 
model systems to humans.[ 180 ] For example, human plasma 
proteome dynamics[ 181 ] was measured following metabolic 
protein labeling of non-labile covalent C±H positions after oral 
dosing of D2O; also see section 2.5.[182]  
2.4. Stable isotopes in metabolomics 
Beyond the broad utility of hydrogen isotopes in proteomics, 
the application of stable isotopes has also emerged in the field 
of metabolomics for system-wide comprehensive analysis of 
metabolites in various organisms, including microbial, animals, 
plants, and humans.[183] 13C-Based tracers are by far the most 
commonly applied substrates because of the well-defined 
carbon transfer in biochemical processes. However, examples of 
deuterium[ 184 ] and 15N applications[ 185 ] in metabolomics also 
exist. Accordingly, stable isotopes are now facilitating advances 
in three main areas of metabolomics research: metabolite 
identification; metabolite quantification; and pathway discovery / 
flux analysis.[186] Structural identification of unknown metabolites 
(untargeted metabolomics) can be assisted by feeding the 
organism of interest with unlabeled and uniformly labeled 
nutrients, respectively, to generate, after mixing, characteristic 
LC-MS patterns which can be exploited in data processing 
steps.[ 187 ] Absolute quantification in MS-based metabolomics 
requires internal standardization in order to avoid matrix effects 
from co-eluting compounds and, thus, a stable labeled authentic 
standard of the metabolites (see also section 2.2.2). 
Alternatively, for spiking individual authentic standards of many 
hundreds of metabolites, fully labeled metabolomes of specific 
organisms can be generated when a fully labeled substrate, e.g. 
13C-glucose, forms the sole carbon source.[188] Recently, in vivo 
labeling has also been extended to plants;[189] however, typically 
for more complex organisms, it may be necessary to use a 
heterologous source of isotope-labeled extract which is then 
spiked into the study samples.[190]  
Similar to ICAT in proteomics (see section 2.3), stable 
isotope-coded derivatization (ICD)[ 191 ] has been introduced in 
metabolomics research to enable non-targeted screening for all 
metabolites belonging to a specific chemical class. As shown in 
Scheme 21, several ICD reagents have been developed to 
support LC/MS analysis by increased sensitivity, ionization 
efficiency, and chromatographic performance, e.g. DiART 
(Deuterium Isobaric Amine Reactive Tag),[ 192 ] DMABS 
(dimethylaminobutyryl succinimide),[ 193 ] and TAHS (p-N,N,N-
trimethylammoniumanilyl N-hydroxysuccinimidyl carbamate 
iodide[194] for amino acids. Additionally, methylation is used for 
modification of amines[195] and glycanes,[196] dansylchloride DNS-
Cl  for dansylation of amines and phenols,[197] as well as DmPA-
Br (p-dimethylaminophenacyl-Br)[ 198 ] and CMP (3-carbinol-1-
methylpyridinium iodide)[199] for organic acids. For GC/MS-based 
metabolomics, silylation with MSTFA (N-methyl-N-
trimethysilyltrifluoroacetamide),[ 200 ] MSTBFA (N-methyl-N-tert-
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butyldimethylsilyltrifluoroacetamide), [ 201 ] and methyl 
chloroformate (MCF)[ 202 ] are most frequently used to make 
analytes less polar and to increase their volatility.  
 
Scheme 21. Stable isotope-coded derivatization (ICD) derivatization reagents 
utilized for metabolomics research.[191] 
 
Analysis of stable isotope enrichment or dilution can 
delineate the active metabolic pathways responsible for the 
production of novel or known metabolites.[203] 13C metabolic flux 
analysis (13C-MFA) using stable isotope assisted metabolomics 
is the key method to analyse and quantify in vivo reaction rates 
(the fluxes) in a biological system.[ 204 ] Metabolism of an 
isotopically-enriched substrate leads to isotopic enrichment in 
downstream metabolites,[205] which can be analyzed by MS and 
NMR to deduce metabolic fluxes.[206] Since the resulting isotopic 
labeling patterns are a direct consequence of metabolic fluxes, 
global analysis of labeling patterns would allow for the global 
detection of metabolic flux changes.[207] In this context, metabolic 
isotope fingerprinting or footprinting are frequently used 
terminologies in metabolomics analysis to distinguish 
intracellular and extracellular metabolite profiling.[208] 
The determination of metabolic fluxes provides detailed 
information of cellular physiology.[ 209 ] Furthermore, the 
assessment of metabolic flux changes upon a certain 
perturbation can provide novel information relating to the 
regulation of pathways[210], their roles in growth,[211] toxicology[212] 
and disease,[213] and, thus, directly facilitate the improvement of 
biotechnological processes[ 214 ] and clinical research.[ 215 ] 
Associated with this, advanced computational tools for data 
analysis, visualization, and flux models to predict comprehensive 
metabolic flux maps on a systems scale have been developed; 
however, the complexity of data handling and analysis still 
remain challenges to be solved.[216] 
2.5. Applications of stable isotopes in clinical 
pharmacology[217] 
Labeling with heavy water (D2O) has been used safely for 
decades as a tracer for physiological studies.[218] At lower doses 
(e.g. 1-2% D in body water) D2O appears to be well tolerated in 
humans even for several months,[219] while rodents were kept at 
3-20% D in body water for months and years without adverse 
events.[ 220 ] However, a recent study demonstrated that the 
deuterium content in drinking water may influence the incidence 
of depression.[ 221 ] After oral dosing of D2O to humans, the 
deuterium equilibrates in water throughout all tissues within 1 h, 
and when D2O administration is discontinued, the label decays 
with a half-life of body water (approx. 1 week).[222] Labeling of 
peptides from body water occurs rapidly at the D-carbon through 
transamination and intermediary metabolism (Scheme 22). 
Subsequently, the deuterium label is incorporated into newly 
synthesized proteins.[223]  
 
Scheme 22. Transamination process for deuterium labeling of proteins from 
D2O.[224] 
This approach has been successfully used to monitor 
skeletal muscle protein synthesis with known perturbations of 
interest to the field of muscle biology, feeding, and exercise 
(Scheme 23).[ 225 ] Furthermore, heavy water labeling can be 
extended to investigate lipid[226]and glucose kinetics,[227] as well 
as total energy expenditure.[228] Recently, experimental protocols 
for measuring cell proliferation based on deuterium incorporation 
from D2O into the deoxyribose moiety of purine 
doxyribonucleotides in the DNA of dividing cells have also been 
described.[229]  
 
Scheme 23. Experimental workflow for human heavy water labeling study. 
Isotopically-enriched drinking water was provided to subjects in the study. 
Endogenous metabolism incorporates deuterium from body water into amino 
acids and proteins. Samples were collected over time. Proteins from these 
samples were separated into different fractions using affinity chromatography 
and then digested for analysis by LC±MS/MS. Subsequent bioinformatic 
analysis of the peptide isotopomer shift was used to calculate kinetics.[182a] 
Besides D2O, [6,6-D2] D-Glucose is the most common 
example of a stable labeled alternative toradioactive analogues, 
for example, to measure the rate of hepatic glucose 
production[ 230 ] and to assess insulin sensitivity and glucose 
effectiveness at basal insulin in the stable labeled intravenous 
glucose tolerance test (IVGTT).[231]   
The stable isotope labeled kinetic (SILK) protocol is one 
approach to study the unnatural accumulation of amyloid 
plaques present in the brDLQVRI$O]KHLPHU¶VSDWLHQWVDVZHOODV 
the related effect of Alzheimer drugs by monitoring the rates of 
E-amyloid peptide production and clearance following 
administration of [13C]L-leucine.[ 232 ] A dual stable isotope 
protocol, involving oral deuterium oxide administration, 
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coincident with constant infusion of sodium [1-13C]acetate, to 
twelve human subjects, was developed for simultaneous  
measurement of fractional and absolute synthetic rates of 
cholesterol.[233] 
Stable isotope tracers also enable quantitation of metabolic 
reactions in vivo.[234] A well- established approach to investigate 
de novo fatty acid synthesis involves the administration of stable 
labeled acetate,[235] glucose,[236] or heavy water.[237] For example, 
the effect of dietary changes on fatty acid metabolism in mice 
can be measured upon D2O labeling.[ 238 ] Another strategy 
involves human administration of a deuterium or 13C-labeled 
fatty acid precusor to study, for example, the effect of 
smoking[239] or diet[240] on fatty acid metabolism, or to elucidate 
postprandial fat disposition.[241] Similar approaches with stable 
labeled fatty acids, glucose, or D2O as precursor[242] can be used 
for dynamic lipidomics,[ 243 ] for example, to investigate the 
regulation of surfactant phospholipid synthesis in human 
volunteers[244] or to assay [U-13C] palmitate incorporation into 
ceramides following muscle biopsy.[245] A more selective and, 
thus, most frequently applied strategy to investigate 
phospholipid metabolism in vivo is the introduction of stable 
labeled head groups into glycerophospholipid by employing D9-
choline and/or D4-ethanolamine.[246]  
Another important field where stable isotope approaches are 
applied in a clinical domain are within one-period, one 
sequence, crossover study designs for determination of 
bioavailability, which is the fraction of an administered drug 
reaching systemic circulation.[247]  Relative bioavailability is used 
to compare different formulations of the same compound (e.g. 
capsule vs. tablet)[248] or to compare a generic version with the 
original drug.[ 249 ] Absolute bioavailability is determined by 
comparing the blood (plasma) concentration-time-curves 
(usually as ³area under the curve´) following extravascular drug 
and concomitant intravenous stable labeled tracer administration 
(Scheme 24).[ 250 ] With the sensitivity improvements of newer 
mass spectrometry instrumentation into the pico-molar or even 
femto-molar range, stable isotope i.v. microdosing[251] has been 
introduced recently for absolute bioavailability determination.[252] 
This developed method has the potential for considerable cost 
and time savings due to reduced safety package 
requirements,[ 253 ] the avoidance of radioactive 14C-tracer 
administration followed by expensive AMS (Accelerated Mass 
spectrometry) analysis,[ 254 ] and the possibility to combine 
absolute bioavailability determination in a double-tracer design 
with conventional radiolabeled human ADME assessment in the 
same study.[255]  
 
Scheme 24. Microdose Study for determination of absolute bioavailability 
using either a 14C or 13C IV microdose.  
 
2.6. Stable isotopes in diagnostics[256] 
Stable isotopes have also advanced the field of diagnostic 
clinical breath tests for indirect, non-invasive assessment of 
several pathophysiological metabolic processes.[ 257 ] 
Replacement of radioactive 14C was an important aspect of 
research in past years in order to reduce the exposure burden 
for patients and to enable pediatric applications. The principle of 
breath tests relies on the concept that the metabolized substrate 
leads to the production of gases (e.g. CO2) excreted in expired 
air, indicating significant changes in metabolism due to a specific 
disease or the lack of a specific enzyme.[258] 13C-breath tests 
involve the ingestion of specific 13C-labeled substrates, followed 
by the collection of serial breath samples for analysis of 13CO2 
enrichment by high resolution isotope ratio mass spectrometers 
(IRMS) or non-dispersive isotope selective infrared 
spectrometers (NDIRS).[259] Possibly the most well known, best 
standardised, and most widely used breath test is the 13C-urea 
breath test detecting gastric Helicobacter pylori infection 
(Scheme 25).[260] Another important field of clinical 13C-breath 
test application is the assessment of gastric emptying kinetics in 
response to meals labeled with 13C-acetate or 13C-octanoic 
acid.[261] Other breath tests have been developed for diagnosis of 
exocrine pancreatic insufficiency,[262] for evaluation of dynamic 
liver function[263] and for assessment of intestinal absorption and 
transport functions[ 264 ] under physiological and pathological 
conditions. 
 
Scheme 25. The urea breath test is a diagnostic test for identification of 
infections by Helicobacter pylori. This spiral bacterium can cause inflammation, 
gastric ulcer, and peptic ulcer disease.  The test is based on the ability of H. 
pylori to convert urea to ammonia and carbon dioxide. Patients swallow a 
capsule with 13C-labeled urea. Detection of 13C-labeled carbon dioxide in 
exhaled breath indicates that the urea was metabolized and, hence, that H. 
pylori bacteria are present in the stomach.[260]  
2.7. Stable isotopes in microbial ecology  
Compound specific isotope analysis (CSIA)[ 265 ] is an 
analytical method to gain information on, for example, 
contaminant sources and extent of degradation, by measuring 
the ratios of naturally occurring stable isotopes in environmental 
samples. The method relies on isotopic fractionation (see 
section 2.1.6) and bears the potential to delineate differences in 
degradation mechanism, e.g. aerobic versus anaerobic, or 
abiotic versus biotic.[266] In contrast, stable isotope probing (SIP) 
involves incorporation of stable isotope labeled growth 
substrates into cellular biomarkers that can be used to identify 
microorganisms assimilating those substrates.[ 267 ] SIP is 
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performed by adding isotopically-labeled substrates (typically 
13C[268] but with 15N[269] and D[270] also being employed) to an 
environmental sample and then analysing the resulting isotope-
labeled biomarkers in the target organisms (Scheme 26). 
Labeled biomarkers, such as DNA or rRNA, can be recovered 
by density gradient centrifugation. Subsequently, metagenomic 
analysis can be performed in order to identify the labeled 
populations.[ 271 ] This approach has been applied to 
phospholipid-derived fatty acids (PLFA-SIP)[ 272 ], nucleic acids 
(DNA-SIP[ 273 ] and RNA-SIP[ 274 ]; (Scheme 26) and proteins 
(protein-SIP).[275] 
Scheme 26. Principle of Stable Isotope Probing (RNA-SIP): SIP is based on 
the incorporation of a 13C-labeled substrate into cellular biomarkers, such as 
nucleic acids, separation of labeled from unlabeled nucleic acids by density 
gradient centrifugation, and molecular identification of active populations 
carrying labeled nucleic acid. 
 
3. Applications of Tritium labeled compounds 
Tritium (3H) is the radioactive isotope of hydrogen. It decays 
with a half-life of 12.32 years to Helium (3He) by emission of 
beta particles with a mean energy of 5.7 keV.[276] The range of 
the emitted soft E-particles is about 6.0 mm in air and 0 mm in 
solid medium and, thus, they are incapable of passing through 
human skin. The emission is sufficiently energetic to make 
measurement by liquid scintillation counting fairly simple, but 
weak enough to make shielding unnecessary. In consequence, 
3H-labeled compounds can be safely handled in standard glass 
vessels and conventional lab equipment if reasonable radiation 
safety precautions are taken. Because of these favourable 
properties, tritium is widely used as a radioactive tracer element 
in biological research.[277] Another important advantage is the 
high specific activity of 28.8 Ci/mmol of tritium, which is 
approximately 500 times greater than that achievable with a 
single carbon-14 label (62.4 mCi/mmol). This property makes 
tritium irreplaceable for the labeling of large molecules, 
particularly biomolecules such as peptides, proteins, 
oligonucleotides, and antibodies.[ 278 ] Noteworthy the kinetic 
isotope effect of tritium is significantly higher compared to 
deuterium.   
The typical sources for the tritium label are tritium gas, other 
tritiated reagents, and, in some instances, tritium water. Labeling 
methods have to be compatible with specific requirements for 
tritium chemistry. In particular, the standard very small scale of 
operation requires special preparative techniques, operator 
training, and elaboration methods.[6] Typically, reactions are 
conducted at reduced pressure (< 1 bar) using modern stainless 
steel manifold systems allowing for the safe handling and 
storage of tritium gas.[ 279 ] Traditional approaches, such as 
double bond reduction, hydride reduction, and tritium±halogen 
exchange require upfront precursor syntheses.[280] Alternatively, 
hydrogen exchange labeling can provide a highly cost- and time 
efficient method if carried out directly on the target molecule 
itself.[811]  
Today, H/T exchange is extensively applied and the very 
high selectivity and efficiency of new homogeneous metal-
catalyzed exchange methods enables specific tritium 
introduction into biologically- and chemically-stable positions. 
Consequently, new hydrogen exchange methods have delivered 
processes to overcome the stability issues associated with 
earlier chemistry limitations, which had often previously created 
a rather conservative attitude towards the use of tritium-labeled 
compounds.[281]  
3.1 Tritium in drug discovery & development 
Tritium facilitates radioligand binding assays which are 
widely used to characterize receptors, to study receptor 
dynamics and localization, to identify novel chemical structures 
that interact with receptors, and to define ligand activity and 
selectivity in normal and diseased tissues.[282] The selection of 
the radioligand is based on stability, selectivity, and a high 
specific activity in the range of 50-100 Ci/mmol, and, thus, 
typically requires introduction of 2-4 tritium atoms. Additionally, 
radioligands should have a high affinity and low non-specific 
binding. 
Receptor affinity and density can be readily determined by 
saturation experiments measuring the dissociation constant and 
number of specific binding sites for the radioligand at 
equilibrium.[ 283 ] This information can be further used in a 
competition assay to determine the ability of unlabeled test 
compounds to displace the radioligand from the same receptor 
binding site. If conducted at different substrate concentrations, 
the IC50-value (analyte concentration displacing 50% of the 
bound radioligand) can be determined. Finally, kinetic 
experiments allow the association (kon) and dissociation (koff) 
rate constants to be determined.[ 284 ] A disadvantage of 
conventional heterogeneous radioligand binding assays with 
membrane-bound receptors is the need to separate free from 
bound ligand, which make these assays labour-intensive and 
relatively slow.  
Alternatively, homogeneous scintillation proximity assays 
(SPA) have been developed where the receptor is immobilized 
on the surface of a solid scintillant beat (Scheme 27).[285] As the 
E-particle emitted from tritium travels only over a limited distance 
of < 8 Pm in aqueous media, only the bound radioligand is in 
close enough proximity to activate the scintillant causing light 
emission and, thus, enables direct measurement without the 
need for separation.[ 286 ] SPA is an excellent tool in high-
throughput inhibitor screening[ 287 ] and was also successfully 
used for functional characterization of different transporter 
proteins.[ 288 ] Commercially available FlashPlates rely on the 
same principle but with the receptor now being immobilized at 
the surface of scintillant coated microtiter plates.[289]  
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Scheme 27. The scintillation proximity assay is based on the emission of light 
as a result of an energy transfer from the radioactive ligand to the scintillant 
beat, containing a scintillant. The emission of light only proceeds if the labeled 
ligand and receptor are in close proximity, otherwise, the energy of the 
radioactive ligand is absorbed by the buffer.  
Tritium labeled analogues are considered most convenient 
for in vitro characterization of positron emission tomography 
(PET) radioligands to determine binding selectivity and kinetics 
since, for practical reasons, this type of experiment requires 
isotopes with a longer half life.[290] PET tracers are increasingly 
utilized as imaging or diagnostic tools, however they are also 
used for in vivo determination of receptor occupancy by 
displacement with a therapeutic drug candidate.[291] Alternatively, 
tritium-labeled comparator compounds can be useful to study or 
confirm a postulated mechanism of action for the drug or drug 
analogues.[ 292 ] Tritium-labeled cholesterol amphiphile probes 
have been designed for cell membrane anchoring and imaging 
of membrane-associated lipoproteins.[293] Additionally, proteolytic 
degradation, and protein aggregation and turnover can be 
determined following, for example, metabolic labeling of cellular 
proteins by substituting one amino acid by its 3H-labeled 
analogue in the culture medium.[294] Sometimes, tritium labeling 
of enantiomers is used to differentiate chiral from non-chiral 
processes, for example, as associated with the binding affinities 
of enantiomers or stereoselective ADME properties.[295] 
New drug candidates are routinely tested for their potential 
to inhibit the uptake of specific tritiated probe substrates 
mediated by transporter proteins known to play an important role 
in drug disposition, drug-drug-interaction, and drug toxicity.[296] 
For example, [3H]-digoxin has been used to investigate P-gp (P-
glycoprotein) mediated transport, [3H]-estradiol-17E-glucuronide 
for OATP1B1 (organic anion transporter proteins), and [3H]-
estrone-3-sulfate for BCRP (breast cancer resistance 
protein).[297] 
 
Scheme 28. Photoaffinity labeling. The ligand specifically binds to the active 
site of the target molecule. Upon light activation a photo reactive group (e.g. 
arylazides, diazirines, or benzophenones) forms a covalent bond to the target. 
Subsequently, a reporter tag (typically a radiolabel, a fluorescence dye, or 
affinity tag) enables isolation/detection of the resulting probe-protein adduct.  
Photoaffinity labeling (PAL) is another powerful biochemical 
technique for the investigation of ligand-protein interactions 
frequently probed in drug discovery to isolate and identify 
unknown molecular targets, to study off-target interactions, and 
for structural elucidation of binding sites.[298] The method is used 
to investigate plasma proteins[299] and lipidic biomembranes,[300] 
and can also be used for activity-based proteomics[301] to study 
enzyme activities and protein complexes. Photoaffinity probes 
typically involve three functionalities: 1. a ligand (affinity unit) for 
reversible and specific binding to the active site of the target 
macromolecule; 2. a photo reactive group (e.g. arylazides, 
diazirines, or benzophenones) for covalent target binding upon 
light activation and generation of highly reactive species; and 3. 
a reporter tag (typically a radiolabel, a fluorescence dye, or an 
affinity tag, such as biotin) for isolation/detection of the resulting 
probe-protein adducts (Scheme 28).[302] In contrast to all other 
identification tags, a tritium label can be introduced without 
altering the chemical structure of the ligand and, thus, preserves 
the affinity towards a target receptor.[303] Additionally, radiolabels 
can be easily measured with high sensitivity and low background 
interference and can also be used for in vivo activity assessment 
in living cells. However, radiolabels provide no direct means for 
isolation and identification of labeled proteins and, therefore, this 
approach is mainly used for profiling of known receptors. For 
target identification, affinity tags (e.g. biotin and short peptide 
sequences) allow for easier enrichment and detection of labeled 
proteins using tag specific antibodies. Having stated this, the 
bulky affinity moiety is not cell permeable and may cause 
potential steric interference. These disadvantages have been 
addressed recently by introducing a two-step tandem 
photoaffinity labeling/biorthogonal conjugation strategy.[ 304 ] 
Following covalent bond formation via photo-irradiation (step 1), 
a post-labeling biorthogonal conjugation (step 2) was used to 
introduce bulky reporter tags, typically via a Click reaction 
through a terminal alkyne and aliphatic azides. In efforts to 
capture low affinity or low abundant proteins, isotope-coded 
photoaffinity probes combining fluorous or fluorogenic tags for 
enrichment with stable isotopes have been developed recently 
(Scheme 29).[305] In this approach cells are treated with equal 
amounts of unlabeled and stable labeled probes separately to 
generate cross-linked products with a characteristic MS pattern 
upon mixing and proteolytic digestion[306] (similar to ICAT, see 
section 2.3). 
 
Scheme 29. Isotope-coded fluorescent tag (IsoFT) and isotope-coded, 
fluorous photoaffinity labeling reagents.[305]  
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As it is generally believed that only unbound drug (free 
fraction of a drug) can interact with the target receptor exerting a 
pharmacological effect, besides receptor binding, another 
important PK/PD parameter that can impact the efficiency of a 
drug is plasma protein binding (PPB).[ 307 ] Interspecies 
differences in PPB may affect drug-safety margins and, thus, a 
careful assessment of unbound drug concentration in human 
and animal plasma is requested by authorities before initiating 
clinical trials (Scheme 30). Typically, techniques such as 
equilibrium dialysis, ultrafiltration, and ultracentrifugation, relying 
on unlabeled  
 
Scheme 30. Plasma Protein Binding (PPB) assay based on equilibrium 
dialysis. After incubation, both the plasma and buffer samples are analyzed for 
drug concentration (LC-MS/MS or radioactivity).  
material, are used in drug discovery to guide structural design 
and lead selection.[308] However, in preclinical drug development 
radiolabeled drugs are often preferred because of the higher 
accuracy of the measurement, particularly in the case of very 
high plasma protein binding.[309]     
As stated in section 2.2.2, in order to allowing the effective 
tracking of a drug molecule throughout a complete physiological 
system, the use of radiolabeled drugs allows both qualitative and 
quantitative assessment of drug distribution, metabolism, and 
excretion (ADME) to be assessed.[310]  
Either 14C or 3H are used as radioactive isotopes in such 
ADME studies, with a general preference for 3H for early in vitro 
assays, driven by the cheaper preparation of such species, and 
14C for later in vivo studies due to of the potential risk of losing a 
tritium label upon oxidative biotransformation and the possibility 
of inducing metabolic isotope effects (see section 2.1.3).[281] 
However, this risk can be also mitigated by careful selection of 
labeling positions and mediated by the application of modern, 
highly selective hydrogen isotope exchange chemistry.  
Because of their relatively low costs and more 
straightforward access, tritium labeled compounds can provide a 
valuable tool to allow early assessment of reactive metabolite 
formation which is considered to be linked to idiosyncratic 
adverse drug reactions, such as drug-induced liver injury 
(DILI).[ 311 ] Nucleophilic trapping agents such as Glutathione 
(GSH) are applied in early stages of drug discovery for reactive 
metabolite detection (see also section 2.2.2) [312] However, at 
candidate selection stage, typically covalent binding assays are 
conducted by incubating radiolabeled drug candidates with 
human microsomes or hepatocytes.[ 313 ] Generally, after 
incubation, residual radioactivity bound to the protein is 
measured following protein precipitation, isolation, and extensive 
washing steps.[314]  
In vitro metabolism cross-species comparison studies with 
radiolabeled drug candidates in hepatocellular and subcellular 
fractions (e.g. rodent, non-rodent, and human) and/or 
recombinant human enzymes provide valuable information on 
metabolic pathways of new chemical entities.[315 ] Additionally, 
the radioactivity allows for a quantitative interspecies 
comparison to ensure that all major metabolites identified in the 
human in vitro system also have a comparable exposure in the 
animal species selected for long-term safety assessment.[316] In 
order to correlate these in vitro generated metabolite profiles, or 
reactive metabolite findings, with the situation in vivo, 
radiolabeled analogues of drug development candidates are 
frequently administered to preclinical species. Besides an 
identification and quantification of circulating and excreted 
metabolites, the main objectives of radiolabeled ADME studies 
may be to determine clearance mechanisms and mass balance 
(through radioactivity recovery).[317]  
Scheme 31. Quantitative Whole Body Audioradiography (QWBA) following 
subcutaneous administration of a tritium labeled drug development candidate.   
QWBA (Quantitative Whole Body Audioradiography) is a 
convenient in vivo imaging method which provides qualitative 
and quantitative information on drug distribution and 
pharmacokinetics by measuring drug-related radioactivity from 
whole body slices or organ sections (Scheme 31).[318] In an in 
vivo sense, these data are important to assess whether the drug 
reaches the target organ or accumulates in tissues associated 
with potential safety issues. QWBA studies are routinely 
conducted for small molecule drug candidates to calculate the 
maximum radioactive dose that can be administered to humans 
in the radiolabeled human ADME study.[319] More recently, this 
technique has also been increasingly utilized to determine 
biodistribution of biotherapeutic drugs, such as antibody-drug 
conjugates, oligonucleotides, fusion proteins, and peptides.[320]  
In conjunction with QWBA, micro-audioradiography (MARG) 
is a histological technique that relies, in particular, on tritium due 
to the short path length of the emitted E-particle providing high 
spatial resolution and, thus, tissue distribution information at the 
cellular level.[ 321 ] MARG is used to address mechanistic 
questions, for example the investigation of receptor binding even 
on the cell surface, and/or to study drug distribution at specific 
sites of individual organs, such as the brain, eye or skin, in order 
to address specific toxicities.[322] Recently, the MARG technique 
was also used to study distribution of humic substances in 
tissues of wheat seedlings using tritiated humic acid derived 
from leonardite (a variety of lignites).[323] However, it should be 
also noted that micro-audioradiography imaging requires 
prolonged exposure time of up to 3-12 months because of the 
weak energy emitted by tritium. In spite of the very high spatial 
resolution of this technique this is often considered too long to 
address pressing mechanistic questions in drug discovery.      




4. Conclusions & Outlook 
The unique MS-pattern obtained from natural and labeled 
isotopologues drastically simplifies analysis and provides a 
wealth of inspiring information and previously unprecedented 
levels of insight from a wide and continuously growing range of 
applications in many disciplines within the life sciences and 
beyond. The ability to measure naturally abundant isotope ratios 
has paved the way for a number of scientific breakthroughs in 
forensic sciences, geochemistry, ecology, and physiology. 
Additionally, analytical approaches incorporating stable isotopes 
have delivered now indispensable tools for relative and absolute 
quantification, for delineation of cellular metabolism, and for 
investigation of responses to various stimuli. Having stated this, 
perhaps most importantly, the employment of such methods 
provides a dynamic view on biosynthethic pathways, protein 
turnover, and systems-wide metabolic networks. Indeed, further 
expansion of isotope labeling to the whole-systems level, 
together with recent advances in bioinformatics, will bring us 
closer to a true systems biology understanding.  
The combination of new ultra-sensitive mass spectrometry 
with stable isotope labeling techniques has advanced to a point 
that some radioactive studies can now be readily replaced by 
stable-isotope techniques. This tendency is expected to continue 
with such isotope approaches becoming key components of the 
new clinical study designs currently being persued, increasing 
the patient safety due to the circumvention of the radioactive 
dose. Furthermore, with the employment of stable isotopes 
having the potential to become even more commonplace in 
metabolomics, proteomics, clinical pharmacology, and other 
associated areas, it is expected that the need for stable 
isotopically labeled compounds will further increase.  
In spite of a general tendency for replacement of 
radiotracer studies in favour of, for example, stable or affinity 
tags in areas such as proteomics, metabolomics, and breath 
testing, tritium has recently seen increased use, particularly in 
pharmaceutical drug discovery. It is expected that this tendency 
will continue because the efforts and costs required for the 
synthesis of radiolabeled compounds is out-balanced by the 
strong sensitivity increase and high reliability of the data 
obtained. Consequently, highly efficient, cost-effective, and 
selective synthesis methods for hydrogen isotope labeling of 
target molecules are required.  As there is no other general 
option to attach a mass tag or a radioactive label to an organic 
molecule, it can be expected that isotopically labeled 
compounds will remain an important tool in life sciences in the 
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